Geron’s Testing of Imetelstat for Myelofibrosis to Continue

Geron Corp. (GERN), ordered this month to stop testing its experimental drug in blood disorders, received permission from U.S. regulators to continue a trial of the compound for a bone marrow disorder.

No new patients will be enrolled in the study of imetelstat for myelofibrosis because of the partial clinical hold by the U.S. Food and Drug Administration, the Menlo Park, California-based company said in a statement today. Current participants must show a clinical benefit to stay in the trial, Geron said.

Geron, which has no products on the market, plunged 62 percent on March 12 after the FDA halted trials of imetelstat in essential thrombocythemia, polycythemia vera and multiple myeloma. The regulator stopped the tests because of the possibility of liver damage, Geron said.

To contact the reporter on this story: Caroline Chen in New York at cchen509@bloomberg.net

To contact the editors responsible for this story: Reg Gale at rgale5@bloomberg.net Bruce Rule, Robert Valpuesta

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.